Mantle Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MNT001 MIFTS: 73	Mantle Cell Lymphoma Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma ³⁸ ¹² ⁷⁶ ⁵³ ⁵⁹ ³⁷ ²⁹ ⁶ ¹⁵

Lymphoma, Mantle Cell ⁵³ ¹³

Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse ⁷³

Malignant Lymphoma - Lymphocytic, Intermediate Differentiation ⁷³

Lymphoma, Mantle-Cell ⁴⁴

Mantle Zone Lymphoma ⁵⁹

Lymphoma Mantle-Cell ⁵⁵

Mcl ⁵⁹

Lcm ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴ ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Non-follicular lymphoma

Mantle cell lymphoma

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

Disease Ontology ¹² DOID:0050746

MeSH ⁴⁴ D020522

Orphanet ⁵⁹ ORPHA52416

MESH via Orphanet ⁴⁵ D020522

ICD10 via Orphanet ³⁴ C83.1

UMLS via Orphanet ⁷⁴ C0555202

KEGG ³⁷ H01464

ICD10 ³³ C83.1

SNOMED-CT via HPO ⁶⁹ 16294009 161832001 262285001 more

UMLS ⁷³ C0334634 C0555202

Sources

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : ⁵³ Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin’s lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s.

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to follicular lymphoma and lymphoma. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are splenomegaly and weight loss

Disease Ontology : ¹² A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : ⁷⁶ Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Sources

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)

#	Related Disease	Score	Top Affiliating Genes
1	follicular lymphoma	32.8	BCL2 BCL6 CCND1 IGH MCL1 MME
2	lymphoma	31.9	ATM BCL2 BCL6 CCND1 EZH2 GAS5
3	prolymphocytic leukemia	31.5	ATM CCND1 CD5 MYC
4	composite lymphoma	31.5	BCL6 CD5 SOX11
5	marginal zone b-cell lymphoma	31.3	BCL2 BCL6 CD5 MME
6	b cell prolymphocytic leukemia	31.3	CD5 MYC TP53
7	follicular lymphoma 1	31.1	BCL2 BCL6 IGH
8	cll/sll	31.0	ATM CCND1 CD5 MME SOX11 TP53
9	peripheral t-cell lymphoma	31.0	BCL6 CD5 MME TP53
10	diffuse large b-cell lymphoma	30.9	BCL6 CD5 EZH2 MDM2 MME MYC
11	leukemia, chronic lymphocytic	30.8	ATM BCL2 BCL6 CCND1 CCND2 CD5
12	lymphoblastic lymphoma	30.8	BCL6 CD5 MME
13	lymphoma, mucosa-associated lymphoid type	30.7	BCL2 BCL6 CCND1 CD5 IGH MME
14	retinoblastoma	30.6	CCND1 MALAT1 MDM2 TP53
15	pancreas adenocarcinoma	30.3	CCND1 MYC TP53
16	leukemia, acute myeloid	30.2	EZH2 MALAT1 MCL1 MME MYC TP53
17	lymphoma, non-hodgkin, familial	30.1	ATM BCL2 BCL6 CCND1 CCND2 CD5
18	myeloma, multiple	30.1	CCND1 CCND2 GAS5 MALAT1 MCL1 MYC
19	lung cancer susceptibility 3	29.8	CCND1 GAS5 MALAT1 TP53
20	bladder cancer	29.4	CCND1 EZH2 GAS5 MALAT1 MDM2 MYC
21	b-cell lymphomas	29.4	BCL2 BCL6 BTK CCND1 CCND2 CD5
22	colorectal cancer	28.9	ATM BCL2 CCND1 CCND2 GAS5 MALAT1
23	breast cancer	28.8	ATM BCL2 CCND1 CCND2 EZH2 GAS5
24	prostate cancer	28.7	BCL2 CCND1 EZH2 GAS5 MALAT1 MCL1
25	lymphoma, small cleaved-cell, diffuse	11.2	BCL2 CCND1
26	diffuse large b-cell lymphoma of the central nervous system	11.2	BCL2 MYC
27	synchronous bilateral breast carcinoma	11.2	ATM CCND1 TP53
28	ring chromosome 7	11.2	MDM2 TP53
29	zika virus infection	11.2	MDM2 TP53
30	hidradenocarcinoma	11.1	BCL2 CCND1 TP53
31	keratocystic odontogenic tumor	11.1	BCL2 CCND1 TP53
32	suppressor of tumorigenicity 3	11.1	BCL2 MYC TP53
33	myxosarcoma	11.1	ATM MDM2 TP53
34	soft tissue sarcoma	11.1	BCL2 MDM2 TP53
35	ectopic thymus	11.1	BCL2 CD5
36	nodal marginal zone b-cell lymphoma	11.1	BCL2 BCL6
37	tracheal lymphoma	11.1	CD5 MME
38	high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement	11.0	BCL2 BCL6 MYC
39	richter's syndrome	11.0	ATM CD5 MYC TP53
40	inflammatory myofibroblastic tumor	11.0	CCND1 MDM2 TP53
41	male reproductive organ cancer	11.0	CCND1 MYC TP53
42	female reproductive organ cancer	11.0	CCND1 MYC TP53
43	ocular cancer	11.0	CCND1 MDM2 MYC TP53
44	li-fraumeni syndrome	11.0	ATM BCL2 MDM2 TP53
45	nervous system cancer	11.0	CCND1 MDM2 MYC TP53
46	gastric lymphoma	11.0	BCL2 BCL6 TP53
47	bile duct carcinoma	11.0	CCND1 MYC TP53
48	dendritic cell thymoma	11.0	BCL2 CD5
49	cervical carcinosarcoma	11.0	BCL2 MME TP53
50	epidural neoplasm	11.0	BCL6 CD5 TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Sources

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

⁵⁹ ³² (show all 9)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	splenomegaly ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001744
2	weight loss ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001824
3	anorexia ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0002039
4	lymphadenopathy ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0002716
5	abnormality of bone marrow cell morphology ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0005561
6	abnormality of the gastrointestinal tract ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0011024
7	fatigue ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0012378
8	fever ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0001945
9	b-cell lymphoma ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death HMECs cells	GR00103-A-0	9.63	BCL6 BMI1 CCND2 MDM2 MYC TP53
2	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.43	ATM BCL2 BMI1 MCL1 MDM2 TP53
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.36	MCL1 TP53 ATM BCL2
4	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.36	BTK CCND1 MCL1 MYC TP53 ATM

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

⁴⁶ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.24	ATM BCL2 BCL6 BTK CCND1 EZH2
2	hematopoietic system	MP:0005397	10.22	ATM BCL2 BCL6 BTK CCND1 CCND2
3	cardiovascular system	MP:0005385	10.21	MDM2 MYC SOX11 TP53 ATM BCL2
4	endocrine/exocrine gland	MP:0005379	10.17	MCL1 MDM2 MYC SOX11 TP53 ATM
5	immune system	MP:0005387	10.17	CCND1 CCND2 CD5 EZH2 MCL1 MDM2
6	homeostasis/metabolism	MP:0005376	10.15	ATM BCL2 BCL6 BTK CCND1 CCND2
7	embryo	MP:0005380	10.06	MDM2 MYC SOX11 TP53 ATM BCL2
8	integument	MP:0010771	10.03	ATM BCL2 BTK CCND1 CD5 EZH2
9	digestive/alimentary	MP:0005381	10.02	BCL2 BTK CCND1 MDM2 MYC SOX11
10	neoplasm	MP:0002006	9.76	ATM BCL2 BTK CCND1 EZH2 MDM2
11	normal	MP:0002873	9.61	BCL6 CCND1 CD5 EZH2 MCL1 MDM2
12	reproductive system	MP:0005389	9.28	ATM BCL2 BCL6 CCND1 CCND2 MCL1

Sources

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Imbruvica ¹⁸ ⁴⁹	IBRUTINIB	Pharmacyclics	November of 2013/February 2014
FDA Label: Imbruvica Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia Indications and Usage: ¹⁸ IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). WaldenstrÃ¶mâs macroglobulinemia (WM) (1.4). DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase BTK Mechanism of Action: ¹⁸ Target: Bruton's tyrosine kinase (Btk) Action: selective inhibitor FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTKâsrole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
2	Revlimid ¹⁸ ⁴⁹	LENALIDOMIDE	Celgene	June 2013
FDA Label: Revlimid Disease/s that Drug Treats:mantle cell lymphoma Indications and Usage: ¹⁸ REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4). DrugBank Targets: ¹⁶ 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2 Mechanism of Action: ¹⁸ Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes Action: activator/inhibitor FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-Î± and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
3	Velcade ¹⁸ ⁴⁹	BORTEZOMIB	Millennium Pharmaceuticals	May 2003
FDA Label: Velcade Disease/s that Drug Treats:Multiple Myeloma Indications and Usage: ¹⁸ VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2) DrugBank Targets: ¹⁶ 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2 Mechanism of Action: ¹⁸ Target: 26S proteasome Action: reversible inhibitor of chymotrypsin-like activity FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

52-24-4

5453

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

147-94-4

6253

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

50-02-2

5743

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

23214-92-8

31703

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

33419-42-0

36462

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

53-03-2

5865

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

174722-31-7

10201696

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

2068-78-2, 57-22-7

5978

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

22916-47-8

4189

Everolimus

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

159351-69-6

6442177

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

53123-88-9

5284616 6436030 46835353

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

31703

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antilymphocyte Serum

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Angiogenesis Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Angiogenesis Modulating Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antiemetics

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antimitotic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Antiviral Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Autonomic Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

BB 1101

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Dexamethasone acetate

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

1177-87-3

Etoposide phosphate

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

glucocorticoids

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Hormones

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

protease inhibitors

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antifungal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Carmustine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

154-93-8

2578

Melphalan

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

148-82-3

4053 460612

Fludarabine

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

21679-14-1, 75607-67-9

30751

Interventional clinical trials:

(show top 50) (show all 967)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	Completed	NCT01833039	Phase 4	Ibrutinib
2	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
3	EDOCH Alternating With DHAP for New Diagnosed Younger MCL	Recruiting	NCT02858804	Phase 4	Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma	Active, not recruiting	NCT01180049	Phase 4	temsirolimus;temsirolimus
5	A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	Not yet recruiting	NCT03190330	Phase 4	Ibrutinib 420 mg;Ibrutinib 560 mg
6	Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	Unknown status	NCT00016887	Phase 3	carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
7	Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma	Unknown status	NCT00641095	Phase 3	cyclophosphamide;fludarabine phosphate
8	Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL	Unknown status	NCT00209222	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9	Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
10	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
11	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
12	Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	Unknown status	NCT00003338	Phase 2, Phase 3
13	Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003337	Phase 3
14	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Unknown status	NCT00002989	Phase 3	busulfan;cyclophosphamide;idarubicin;melphalan
15	Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	Unknown status	NCT00053768	Phase 3	EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
16	Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00052936	Phase 3	CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
17	Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00028717	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18	Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma	Unknown status	NCT00003924	Phase 3
19	Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy	Completed	NCT01646021	Phase 3	Ibrutinib;Temsirolimus
20	Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma	Completed	NCT00722137	Phase 3	Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
21	Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study	Completed	NCT00877006	Phase 3	bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22	Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)	Completed	NCT01073163	Phase 3	Bendamustine;Rituximab
23	Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	Completed	NCT00003280	Phase 3
24	Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)	Completed	NCT00117598	Phase 3	Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
25	Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab	Completed	NCT01456351	Phase 3	Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
26	Mantel Cell Lymphoma Efficacy of Rituximab Maintenance	Completed	NCT00921414	Phase 3	Rituximab
27	Bendamustine Plus Rituximab Versus CHOP Plus Rituximab	Completed	NCT00991211	Phase 3	Bendamustine;Standard chemotherapy CHOP + Ritiximab
28	A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma	Completed	NCT00269113	Phase 3	rituximab [MabThera/Rituxan];Standard chemotherapy
29	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	Completed	NCT00799461	Phase 3
30	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
31	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
32	Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial	Completed	NCT00750009	Phase 3
33	American Ginseng in Treating Patients With Fatigue Caused by Cancer	Completed	NCT00719563	Phase 3	American ginseng
34	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain	Completed	NCT00666211	Phase 3
35	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer	Completed	NCT00661999	Phase 3	sodium ferric gluconate complex in sucrose
36	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
37	St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer	Completed	NCT00005805	Phase 3
38	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	NCT00003805	Phase 3	piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
39	Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter	Completed	NCT00006083	Phase 3	Fragmin
40	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer	Completed	NCT00070382	Phase 3	darbepoetin alfa;epoetin alfa
41	Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
42	Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma	Completed	NCT00005590	Phase 3	levofloxacin
43	Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients	Completed	NCT00003938	Phase 3	liposomal amphotericin B
44	Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	Completed	NCT00003341	Phase 3
45	Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant	Completed	NCT00305851	Phase 3
46	Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer	Completed	NCT00265837	Phase 3
47	Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma	Completed	NCT00278421	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
48	Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Completed	NCT00278408	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
49	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	NCT00004230	Phase 3	captopril;cyclophosphamide
50	Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation	Completed	NCT00014391	Phase 3	ribavirin

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

ibrutinib

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743

Cochrane evidence based reviews: lymphoma, mantle-cell

Sources

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

#	Genetic test	Affiliating Genes
1	Mantle Cell Lymphoma ²⁹

Sources

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

⁴¹

B Cells, Bone, Bone Marrow, T Cells, Kidney, Liver, Lymph Node

Sources

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1131)

#	Title	Authors	Year
1	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. ( 29805746 )	Broccoli A....Zinzani P.L.	2018
2	Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )	Inwards D.J....Witzig T.E.	2018
3	The B cell receptor signaling pathway in mantle cell lymphoma. ( 29861875 )	Merolle M.I....Wang M.L.	2018
4	Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )	Zheng Q.F....Nong B.	2018
5	Wogonin Inhibits Growth of Mantle Cell Lymphoma Cells through Nuclear Factor-I_B Signaling Pathway. ( 29451160 )	Xu P.P....Ouyang J.	2018
6	Spontaneous regression of mantle cell lymphoma: a report of four cases. ( 29843782 )	Ye H....Wang M.L.	2018
7	Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients. ( 29363157 )	Joshi K....Bishton M.J.	2018
8	Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception. ( 29434133 )	Matsueda K....Horii J.	2018
9	In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. ( 29880608 )	Perez-Salvia M....Esteller M.	2018
10	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. ( 29912596 )	Agarwal R....Tam C.S.	2018
11	Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2. ( 29901111 )	Xie Y....Shi J.	2018
12	Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma. ( 29273915 )	Lokvenc M....Kodet R.	2018
13	Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome. ( 29869903 )	Aqil B....Kreisel F.	2018
14	Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. ( 29385883 )	Ettleson M....Marini B.L.	2018
15	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. ( 29912594 )	Calzada O....Cohen J.B.	2018
16	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. ( 29794145 )	Eskelund C.W....nbA	2018
17	Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. ( 29963932 )	Sandoval-Sus J.D....Ayala E.	2018
18	NF-I_B signaling and its relevance to the treatment of mantle cell lymphoma. ( 29907126 )	Balaji S....Wang M.	2018
19	Rac1 is a novel therapeutic target in mantle cell lymphoma. ( 29434202 )	Tian T....Fu K.	2018
20	MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. ( 29979193 )	Li W....Zhang M.	2018
21	Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. ( 29872501 )	Yu J....Kipps T.J.	2018
22	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? ( 29415598 )	Marrero W.D....Cabanillas F.	2018
23	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. ( 29441438 )	Restelli V....Carrassa L.	2018
24	Commentary on: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. ( 29380057 )	Goungounga J.A....Giorgi R.	2018
25	Can we improve on ibrutinib in mantle cell lymphoma? ( 29396093 )	Rule S.	2018
26	Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. ( 29910833 )	Sun K....Pingali S.R.	2018
27	Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice. ( 29898964 )	Hayakawa K....Hardy R.R.	2018
28	Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. ( 29383700 )	Jiang H....Tao J.	2018
29	Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. ( 29961897 )	Yu D....Shi J.	2018
30	R-High-CHOP/CHASER/LEED with AutologousA Stem Cell Transplantation in Newly DiagnosedA Mantle Cell Lymphoma: JCOG0406. ( 29957865 )	Ogura M....Tsukasaki K.	2018
31	Current trials for frontline therapy of mantle cell lymphoma. ( 29374487 )	Steiner R.E....Wang M.	2018
32	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. ( 29954415 )	Chen R.W....Holmberg L.A.	2018
33	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. ( 29396091 )	Jerkeman M....nbA	2018
34	Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. ( 29392403 )	Yan X....Jin J.	2018
35	Frontline Treatment for Older Patients with Mantle Cell Lymphoma. ( 29895632 )	Ye H....Wang M.L.	2018
36	Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )	Arvidsson G....Wright A.P.	2018
37	A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. ( 29882587 )	McKay P....Rule S.	2018
38	CD40L mediated alternative NFI_B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. ( 29367645 )	Rauert-Wunderlich H....Rosenwald A.	2018
39	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. ( 28561694 )	Cohen J.B....Kahl B.S.	2017
40	Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). ( 28911068 )	Dabaja B.S....Yahalom J.	2017
41	Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )	Karlin J....Kirzhner M.	2017
42	Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. ( 28434928 )	Salhotra A....Chen R.	2017
43	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. ( 28533307 )	Balsas P....Amador V.	2017
44	Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. ( 27338091 )	Mohanty S....Ngo V.N.	2017
45	Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )	Cherukuri A.R....DeStigter K.K.	2017
46	Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. ( 29043141 )	Miyata K.N....Winchester J.F.	2017
47	Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )	Zaja F....Fanin R.	2017
48	Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. ( 28495928 )	Wang H.Y....Hodkoff A.	2017
49	Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )		2017
50	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )	Ma J....Xie Y.	2017

Sources

Genes for Mantle Cell Lymphoma

Genes related to Mantle Cell Lymphoma (4 elite genes):

(show all 43)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ATM	ATM Serine/Threonine Kinase	Protein Coding	810.59	Pathogenic ⁶ Causative somatic mutation ⁵⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Functions Variants (show sections)	16956411
2	CCND1	Cyclin D1	Protein Coding	407.25	Causative somatic mutation ⁵⁹ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Functions (show sections)	20062012 9846986 8204893 (more) 7772515 9010577 9209645 7918073 8695815 16448697 17145584 8172819 8172823 18606985
2	CCND1::MIR16-1 ⁴⁷	MIR16-1 Macro RNA (hsa-miR-16-1) targets CCND1
3	IGH	Immunoglobulin Heavy Locus	Protein Coding	357.72	Causative somatic mutation ⁵⁹ GeneCards inferred via : Publications (show sections)
4	MIR16-1	MicroRNA 16-1 Truncated CCND1 mRNA expression leads to increased total CCND1 mRNA, increased CCND1 protein expression, and increased S phase fraction in MCL cell lines. This truncation deletes miR-16-1 binding sites within the CCND1 mRNA 3'UTR and alters miRNA regulation of MCL.	RNA Gene	357.17	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	18483394
5	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1 We found that the expression of MALAT1 was elevated in human MCL tumors and cell lines as compared to normal controls, and the elevated levels of MALAT1 correlated with higher MCL international prognostic index (MIPI) and reduced overall survival. Dysfunction Pattern: Expression [high expression]	RNA Gene	156.82	Experimental evidence: Expression ³⁹ GeneCards inferred via : Publications (show sections)	27998273
6	ROR1-AS1	ROR1 Antisense RNA 1 As a result, several novel lncRNAs were found significantly overexpressed in the MCL samples with lncRNA ROR1-AS1 the most significant one. We cloned the ROR1-AS1 lncRNA in expression vector and ectopically transfected in MCL cell lines. Results showed that overexpression of ROR1-AS1 lncRNA promoted growth of MCL cells while decreased sensitivity to the treatment with drugs ibrutinib and dexamethasone. ROR-AS1 overexpression also decreased the mRNA expression of P16 (P = 0.21), and SOX11 (p = 0.017), without much effect on P53, ATM and P14 mRNA. RNA-immunoprecipitation assays demonstrated high affinity binding of lncRNA ROR1-AS1 with EZH2 and SUZ12 proteins of the polycomb repressive complex-2 (PRC2). Suppressing EZH2 activity with pharmacological inhibitor GSK343 abolished binding of ROR1-AS1 with EZH2. Dysfunction Pattern: Expression [overexpression]	RNA Gene	155.1	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	29113297
7	GAS5	Growth Arrest Specific 5 Stimulation of expression of candidate tumor suppressor GAS5 is responsible for much of the cytotoxic and cytostatic effects of rapalogues in MCL Dysfunction Pattern: Regulation	RNA Gene	150	Experimental evidence: Regulation ³⁹	24703244
8	BMI1	BMI1 Proto-Oncogene, Polycomb Ring Finger	Protein Coding	29.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11389032 16528373
9	BCL6	B Cell CLL/Lymphoma 6	Protein Coding	29.48	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9209651
10	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	29.44	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11389032
11	BCL2	BCL2, Apoptosis Regulator	Protein Coding	27.71	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9090492 8172819
12	SOX11	SRY-Box 11	Protein Coding	26.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CD5	CD5 Molecule	Protein Coding	26.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	MDM2	MDM2 Proto-Oncogene	Protein Coding	26.55	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17488676
15	BTK	Bruton Tyrosine Kinase	Protein Coding	24.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	TP53	Tumor Protein P53	Protein Coding	24.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CCND2	Cyclin D2	Protein Coding	24.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	24.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	MCL1	MCL1, BCL2 Family Apoptosis Regulator	Protein Coding	24.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	MME	Membrane Metalloendopeptidase	Protein Coding	24.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	24.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CD19	CD19 Molecule	Protein Coding	23.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	PMAIP1	Phorbol-12-Myristate-13-Acetate-Induced Protein 1	Protein Coding	23.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	CCND3	Cyclin D3	Protein Coding	23.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	CCNG1	Cyclin G1	Protein Coding	18.04	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9209645
26	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	13.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	13.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
28	CDK4	Cyclin Dependent Kinase 4	Protein Coding	13.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
29	CD200	CD200 Molecule	Protein Coding	13.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
30	BCL2L1	BCL2 Like 1	Protein Coding	12.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
31	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	12.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
32	ROR1	Receptor Tyrosine Kinase Like Orphan Receptor 1	Protein Coding	12.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
33	MIR17HG	MiR-17-92a-1 Cluster Host Gene	RNA Gene	12.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
34	SETMAR	SET Domain And Mariner Transposase Fusion Gene	Protein Coding	12.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
35	PARP1	Poly(ADP-Ribose) Polymerase 1	Protein Coding	12.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
36	CASP3	Caspase 3	Protein Coding	12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
37	CD40LG	CD40 Ligand	Protein Coding	12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
38	CD40	CD40 Molecule	Protein Coding	11.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
39	SYK	Spleen Associated Tyrosine Kinase	Protein Coding	11.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
40	ITGAX	Integrin Subunit Alpha X	Protein Coding	11.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
41	CD74	CD74 Molecule	Protein Coding	11.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
42	MALT1	MALT1 Paracaspase	Protein Coding	11.81	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
43	PAX5	Paired Box 5	Protein Coding	11.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ATM	NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly)	single nucleotide variant	Pathogenic	rs121434221	GRCh37	Chromosome 11, 108199926: 108199926
2	ATM	NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly)	single nucleotide variant	Pathogenic	rs121434221	GRCh38	Chromosome 11, 108329199: 108329199
3	ATM	NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys)	duplication	Pathogenic	rs796051857	GRCh38	Chromosome 11, 108329182: 108329184
4	ATM	NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys)	duplication	Pathogenic	rs796051857	GRCh37	Chromosome 11, 108199909: 108199911
5	ATM	NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter)	single nucleotide variant	Pathogenic	rs121434222	GRCh37	Chromosome 11, 108158414: 108158414
6	ATM	NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter)	single nucleotide variant	Pathogenic	rs121434222	GRCh38	Chromosome 11, 108287687: 108287687

Cosmic variations for Mantle Cell Lymphoma:

⁹

(show top 50) (show all 362)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM3733325	ZNF296	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.488G>A	p.G163D	19:45072541-45072541	7
2	COSM212352	ZFHX3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.4136C>T	p.T1379M	16:72798546-72798546	7
3	COSM3733324	UBR5	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.6190G>A	p.E2064K	8:102278924-102278924	7
4	COSM3733267	UBR5	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.8147C>G	p.S2716*	8:102257672-102257672	7
5	COSM44687	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.379T>C	p.S127P	17:7675233-7675233	7
6	COSM10662	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.743G>A	p.R248Q	17:7674220-7674220	7
7	COSM10705	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.586C>T	p.R196*	17:7674945-7674945	7
8	COSM11450	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.644G>T	p.S215I	17:7674887-7674887	7
9	COSM44309	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.440T>G	p.V147G	17:7675172-7675172	7
10	COSM10749	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.830G>T	p.C277F	17:7673790-7673790	7
11	COSM10659	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.817C>T	p.R273C	17:7673803-7673803	7
12	COSM43651	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.763A>T	p.I255F	17:7674200-7674200	7
13	COSM43826	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.706T>A	p.Y236N	17:7674257-7674257	7
14	COSM43814	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.587G>C	p.R196P	17:7674944-7674944	7
15	COSM10724	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.839G>C	p.R280T	17:7673781-7673781	7
16	COSM10648	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.524G>A	p.R175H	17:7675088-7675088	7
17	COSM44467	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.497C>G	p.S166*	17:7675115-7675115	7
18	COSM11089	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.584T>C	p.I195T	17:7674947-7674947	7
19	COSM10656	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.742C>T	p.R248W	17:7674221-7674221	7
20	COSM44962	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.774A>T	p.E258D	17:7674189-7674189	7
21	COSM11123	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.838A>G	p.R280G	17:7673782-7673782	7
22	COSM44571	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.581T>G	p.L194R	17:7674950-7674950	7
23	COSM10660	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.818G>A	p.R273H	17:7673802-7673802	7
24	COSM10667	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.646G>A	p.V216M	17:7674885-7674885	7
25	COSM6901	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.559+1G>A	p.?	17:7675052-7675052	7
26	COSM44972	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.831T>A	p.C277*	17:7673789-7673789	7
27	COSM43846	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.487T>C	p.Y163H	17:7675125-7675125	7
28	COSM10786	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.949C>T	p.Q317*	17:7673579-7673579	7
29	COSM10883	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.731G>A	p.G244D	17:7674232-7674232	7
30	COSM11114	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.528C>G	p.C176W	17:7675084-7675084	7
31	COSM10758	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.659A>G	p.Y220C	17:7674872-7674872	7
32	COSM6987278	TGFBR1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.782G>A	p.G261E	9:99138066-99138066	7
33	COSM6987493	STAT3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.724G>T	p.D242Y	17:42337508-42337508	7
34	COSM3733439	SMC1A	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2398C>G	p.Q800E	23:53403588-53403588	7
35	COSM3733438	SMC1A	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2400G>T	p.Q800H	23:53403586-53403586	7
36	COSM3733287	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.4600C>A	p.Q1534K	19:11058854-11058854	7
37	COSM3733280	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3724G>T	p.E1242*	19:11033467-11033467	7
38	COSM3733500	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3565C>G	p.R1189G	19:11033308-11033308	7
39	COSM3733331	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2897G>A	p.R966Q	19:11023555-11023555	7
40	COSM3733266	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3186C>G	p.H1062Q	19:11026317-11026317	7
41	COSM3733301	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2641G>A	p.D881N	19:11021749-11021749	7
42	COSM3733382	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3109A>T	p.N1037Y	19:11025449-11025449	7
43	COSM3733285	SI	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1825T>C	p.W609R	3:165046903-165046903	7
44	COSM3733321	SI	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1126C>T	p.R376W	3:165059922-165059922	7
45	COSM3733430	SALL3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3044C>T	p.S1015F	18:78995035-78995035	7
46	COSM3733372	ROBO2	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2083C>T	p.R695*	3:77574610-77574610	7
47	COSM3733347	ROBO2	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.964G>A	p.D322N	3:77546367-77546367	7
48	COSM3733492	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1535T>A	p.L512*	13:48381283-48381283	7
49	COSM171725	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.838G>T	p.E280*	13:48362934-48362934	7
50	COSM3733293	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2570G>T	p.R857L	13:48476750-48476750	7

Copy number variations for Mantle Cell Lymphoma from CNVD:

⁷ (show all 39)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	44978	10	6600000	12200000	Loss		Mantle cell lymphoma
2	49103	11	102900000	110400000	Loss	ACAT	Mantle cell lymphoma
3	49104	11	102900000	110400000	Loss	ATM	Mantle cell lymphoma
4	49105	11	102900000	110400000	Loss	CUL5	Mantle cell lymphoma
5	49106	11	102900000	110400000	Loss	FDX1	Mantle cell lymphoma
6	49107	11	102900000	110400000	Loss	NPAT	Mantle cell lymphoma
7	49108	11	102900000	110400000	Loss	RAB39	Mantle cell lymphoma
8	49703	11	110400000	112500000	Loss		Mantle cell lymphoma
9	49990	11	112500000	114500000	Loss	TMPRSS5	Mantle cell lymphoma
10	49991	11	112500000	114500000	Loss	USP28	Mantle cell lymphoma
11	49992	11	112500000	114500000	Loss	ZW10	Mantle cell lymphoma
12	54401	11	43500000	48800000	Loss	TP53I11	Mantle cell lymphoma
13	60881	11	92800000	97200000	Loss	MAML2	Mantle cell lymphoma
14	61262	11	97200000	102100000	Loss	BIRC2	Mantle cell lymphoma
15	61263	11	97200000	102100000	Loss	BIRC3	Mantle cell lymphoma
16	74176	13	101700000	104800000	Loss	BIVM	Mantle cell lymphoma
17	74177	13	101700000	104800000	Loss	ERCC5	Mantle cell lymphoma
18	74178	13	101700000	104800000	Loss	KDELC1	Mantle cell lymphoma
19	74694	13	110300000	115169878	Loss	C13orf11	Mantle cell lymphoma
20	74695	13	110300000	115169878	Loss	C13orf17	Mantle cell lymphoma
21	74696	13	110300000	115169878	Loss	CUL4A	Mantle cell lymphoma
22	74697	13	110300000	115169878	Loss	GRTP1	Mantle cell lymphoma
23	74698	3	117011831	117647068	Loss	LAMP	Mantle cell lymphoma
24	74699	13	110300000	115169878	Loss	TFDP1	Mantle cell lymphoma
25	77990	13	48877883	49056026	Deletion	RB1	Mantle cell lymphoma
26	79883	13	79000000	95000000	Copy number	miR-17-92	Mantle cell lymphoma
27	80925	13	99300000	101700000	Loss	PCCA	Mantle cell lymphoma
28	118115	17	7571720	7590868	Mutation	P53	Mantle cell lymphoma
29	141432	2	210288771	210598834	Deletion	MAP2	Mantle cell lymphoma
30	143512	2	237300000	243199373	Loss		Mantle cell lymphoma
31	170852	3	160700000	167600000	Loss	SLITRK3	Mantle cell lymphoma
32	245172	9	102600000	108200000	Loss	INVS	Mantle cell lymphoma
33	248837	9	137400000	141213431	Loss	TRAF2	Mantle cell lymphoma
34	250734	9	21967751	21994490	Deletion	CDKN2A	Mantle cell lymphoma
35	252714	9	36300000	38400000	Loss	MELK	Mantle cell lymphoma
36	254747	9	68700000	72200000	Loss	TJP2	Mantle cell lymphoma
37	256309	9	91800000	93900000	Loss	DIRAS2	Mantle cell lymphoma
38	256992	9	99300000	102600000	Loss	GPR51	Mantle cell lymphoma
39	256993	9	99300000	102600000	Loss	TBC1D2	Mantle cell lymphoma

Sources

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Sources

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.97	ATM BCL2 CCND1 CCND2 MCL1 MDM2
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.88	BCL2 CCND1 MDM2 MYC TP53
3	Pathways in cancer ³⁷	12.87	BCL2 CCND1 CCND2 MDM2 MYC TP53
4	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁷ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.84	ATM BCL2 MCL1 MDM2 MYC TP53
5	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.8	ATM BCL2 CCND1 CCND2 MDM2 TP53
6	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.73	ATM BCL2 CCND1 MDM2 MYC TP53
7	Regulation of IFNA signaling ⁶⁶ Show member pathways Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Jak-STAT signaling pathway ³⁷	12.68	BCL2 CCND1 CCND2 MCL1 MYC
8	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.58	ATM CCND1 CCND2 MDM2 MYC TP53
9	DNA Damage ⁴	12.55	ATM CCND1 CCND2 MDM2 TP53
10	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.49	BCL2 CCND1 CCND2 MYC
11	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.49	CCND1 MDM2 MYC TP53
12	HTLV-I infection ³⁷	12.46	ATM CCND1 CCND2 MYC TP53
13	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.45	ATM BCL2 MDM2 TP53
14	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ Cyclin D associated events in G1 ⁶⁶ G1 Phase ⁶⁶ G1-S Phase Transition ⁶⁴ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶⁶	12.37	ATM CCND1 CCND2 TP53
15	Cell cycle ¹ ³⁷	12.36	ATM CCND1 CCND2 MDM2 MYC TP53
16	Epstein-Barr virus infection ³⁷	12.31	BCL2 MDM2 MYC TP53
17	Proteoglycans in cancer ³⁷	12.31	CCND1 MDM2 MYC TP53
18	Viral carcinogenesis ³⁷	12.31	CCND1 CCND2 MDM2 TP53
19	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.26	ATM BCL2 CCND1 MDM2 TP53
20	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.23	ATM BCL2 CCND1 CCND2 MDM2 MIR16-1
21	Colorectal Cancer Metastasis ⁶⁴	12.21	CCND1 CCND2 MYC TP53
22	Cellular senescence (KEGG) ³⁷	12.18	ATM CCND1 CCND2 MDM2 MYC TP53
23	Transcriptional misregulation in cancer ³⁷	12.18	ATM BCL6 BMI1 CCND2 MDM2 MYC
24	AKT Signaling Pathway ⁶⁷	12.17	BCL2 CCND1 MDM2 MYC TP53
25	Integrated Breast Cancer Pathway ¹	12.14	ATM BCL2 CCND1 MDM2 MYC TP53
26	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	12.11	BCL2 BTK CCND2 MYC
27	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.11	ATM BCL6 CCND1 CCND2 MDM2
28	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.08	CCND1 CCND2 MYC
29	SMAD Signaling Network ⁶⁴	12.08	ATM BCL2 MDM2 TP53
30	Direct p53 effectors ¹	12.08	BCL2 BCL6 MCL1 MDM2 TP53
31	Development IGF-1 receptor signaling ²² Show member pathways Signal transduction AKT signaling ²²	12.05	CCND1 CCND2 MDM2 MYC TP53
32	Thyroid hormone signaling pathway ³⁷	12.03	CCND1 MDM2 MYC TP53
33	Glioblastoma Multiforme ⁶⁴	12.01	CCND1 MDM2 MYC TP53
34	Senescence and Autophagy in Cancer ¹	11.98	BCL2 BMI1 MDM2 TP53
35	Interleukin-4 and 13 signaling ⁶⁶	11.97	BCL2 BCL6 CCND1 MCL1 MYC TP53
36	Small cell lung cancer ³⁷	11.91	BCL2 CCND1 MYC TP53
37	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO Receptor Signaling ¹ EPO signaling pathway ¹	11.9	BCL2 BTK MYC
38	NF-kappa B signaling pathway ³⁷	11.89	ATM BCL2 BTK
39	Retinoblastoma (RB) in Cancer ¹	11.87	CCND1 MDM2 MYC TP53
40	ATM Pathway ⁶⁴ Show member pathways ATM Signaling Pathway ¹	11.84	ATM MDM2 TP53
41	MicroRNAs in cancer ³⁷	11.84	ATM BCL2 BMI1 CCND1 CCND2 EZH2
42	Validated targets of C-MYC transcriptional activation ¹	11.82	BMI1 CCND2 MYC TP53
43	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.8	CCND1 CCND2 MYC
44	C-MYB transcription factor network ¹	11.79	BCL2 CCND1 MYC
45	Bladder cancer ³⁷ ¹	11.77	CCND1 MDM2 MYC TP53
46	E2F transcription factor network ¹	11.76	ATM MCL1 MYC
47	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.76	ATM MDM2 TP53
48	Platinum drug resistance ³⁷	11.76	ATM BCL2 MDM2 TP53
49	IL2 signaling events mediated by PI3K ¹ Show member pathways IL2 signaling events mediated by STAT5 ¹	11.72	BCL2 CCND2 MYC
50	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.71	ATM MYC TP53

Sources

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.36	ATM BCL2 BCL6 BMI1 CCND1 CCND2

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 36)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of apoptotic process	GO:0042981	9.99	ATM BCL2 BCL6 MCL1 TP53
2	negative regulation of gene expression	GO:0010629	9.93	EZH2 MDM2 MYC SOX11
3	cellular response to DNA damage stimulus	GO:0006974	9.88	ATM BCL2 BCL6 CCND1 MYC TP53
4	regulation of cell cycle	GO:0051726	9.86	ATM BCL2 CCND1 CCND2
5	response to estradiol	GO:0032355	9.85	CCND1 EZH2 MYC
6	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.8	ATM MDM2 TP53
7	negative regulation of apoptotic process	GO:0043066	9.8	BCL2 BCL6 CCND2 MCL1 MDM2 MYC
8	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.78	ATM BCL2 MCL1
9	cellular response to hypoxia	GO:0071456	9.78	BCL2 MDM2 MYC TP53
10	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.77	BCL2 EZH2 MIR16-1
11	regulation of gene expression	GO:0010468	9.77	BCL2 BMI1 EZH2 MDM2 MYC
12	positive regulation of cell cycle	GO:0045787	9.76	CCND1 MDM2 MYC
13	cellular response to organic substance	GO:0071310	9.75	BCL2 CCND1 MDM2
14	ovarian follicle development	GO:0001541	9.74	ATM BCL2 MYC
15	response to steroid hormone	GO:0048545	9.72	BCL2 CCND1 MDM2
16	liver regeneration	GO:0097421	9.71	CCND1 EZH2 MYC
17	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.69	BCL2 MIR16-1 TP53
18	cellular response to estrogen stimulus	GO:0071391	9.67	MDM2 MYC
19	regulation of mitochondrial membrane permeability	GO:0046902	9.66	BCL2 TP53
20	determination of adult lifespan	GO:0008340	9.66	ATM TP53
21	response to magnesium ion	GO:0032026	9.65	CCND1 MDM2
22	oocyte development	GO:0048599	9.65	ATM BCL2
23	positive regulation of response to DNA damage stimulus	GO:2001022	9.65	ATM MYC
24	cellular response to X-ray	GO:0071481	9.64	ATM CCND2
25	positive regulation of histone deacetylation	GO:0031065	9.64	BCL6 TP53
26	mitotic G1 DNA damage checkpoint	GO:0031571	9.63	CCND1 TP53
27	response to gamma radiation	GO:0010332	9.63	BCL2 MYC TP53
28	re-entry into mitotic cell cycle	GO:0000320	9.61	CCND1 MYC
29	cellular response to gamma radiation	GO:0071480	9.61	ATM MDM2 TP53
30	response to iron ion	GO:0010039	9.5	BCL2 CCND1 MDM2
31	cellular response to actinomycin D	GO:0072717	9.49	MDM2 TP53
32	cytokine-mediated signaling pathway	GO:0019221	9.43	BCL2 BCL6 CCND1 MCL1 MYC TP53
33	replicative senescence	GO:0090399	9.33	ATM MME TP53
34	negative regulation of transcription by RNA polymerase II	GO:0000122	9.23	BCL6 BMI1 CCND1 EZH2 MDM2 MYC
35	cell proliferation	GO:0008283	10.02	BCL2 CD5 MYC SOX11 TP53
36	positive regulation of cell proliferation	GO:0008284	10	BCL2 CCND1 CCND2 MDM2 MYC SOX11

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	BH3 domain binding	GO:0051434	8.96	BCL2 MCL1
2	promoter-specific chromatin binding	GO:1990841	8.8	BMI1 EZH2 TP53

Sources

Sources for Mantle Cell Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Mantle Cell Lymphoma

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Characteristics:

Orphanet epidemiological data:

Classifications:

External Ids:

Summaries for Mantle Cell Lymphoma

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

Genes for Mantle Cell Lymphoma

Genes related to Mantle Cell Lymphoma (4 elite genes):

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

Cosmic variations for Mantle Cell Lymphoma:

Copy number variations for Mantle Cell Lymphoma from CNVD:

Expression for Mantle Cell Lymphoma

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Sources for Mantle Cell Lymphoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :